Moreover, LPS, which is a TLR4 agonist, counteracted the impacts of TEAS, indicating that the TLR4/MyD88/NF-κB pathway exerts vital effects on the defensive mechanisms of TEAS against ischemic stroke. This evidence concerns the gene MYD88 and ischemic stroke.